-
Mashup Score: 3Avenzo follows Bristol’s lead - 1 day(s) ago
The private group taps DualityBio for an EGFR x HER3 ADC.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6More bad vibes kill off Merck’s TIGIT and Lag3 - 23 day(s) ago
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: More bad vibes kill off $MRK's TIGIT and Lag3. My take for @ApexOnco $RHHBY $AZN $GSK $GILD https://t.co/I1v3LVqyEk http…
-
-
Mashup Score: 5Another pan-KRAS project enters the clinic - 27 day(s) ago
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: Another pan-KRAS project enters the clinic, plus other first-in-human trial starts https://t.co/rXIXMq13fs
-
-
Mashup Score: 7ASH 2024 – J&J mounts its first-line menin challenge - 1 month(s) ago
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: $JNJ mounts its first-line menin challenge, but $KURA could still have the edge #ASH24 $SNDX https://t.co/GjHM86POIm http…
-
-
Mashup Score: 6A fourth challenger from DualityBio and BioNTech - 1 month(s) ago
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: Why B7-H3 data from $BNTX & Dualitybio put Medilink in the partnering frame, via @ApexOnco -> https://t.co/t12o4lGCZC $MRK…
-
-
Mashup Score: 5Relay passes on the lirafugratinib baton - 1 month(s) ago
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: $RLAY passes on the lirafugratinib baton https://t.co/9SBmWdsRxR https://t.co/pCMAXDqNdu
-
-
Mashup Score: 2Looking for an ivonescimab encore - 2 month(s) ago
What similarly acting projects are still unpartnered?
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: Time to look at this list again https://t.co/ykjeZCfbDV $MRK $BNTX $SMMT https://t.co/HGaLjFsjkb
-
-
Mashup Score: 4ASH 2024 preview – more challenges to the BTK order - 2 month(s) ago
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: Challenging the established BTK order at #ASH24, via @ApexOnco -> https://t.co/6ZfxWKDEVv $ABBV $JNJ $BGNE $LLY $NRIX
-
-
Mashup Score: 5FDA red and green lights: October 2024 - 2 month(s) ago
October’s US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: October's FDA oncology approvals, via @ApexOnco -> https://t.co/SbpUL9HBgT $RHHBY $AMGN $ALPMF $BMY $NVS https://t.co/KfOB…
-
-
Mashup Score: 5BeiGene tries where others failed - 3 month(s) ago
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: More first-in-human trial initiations from $BGNE: CEACAM5, PRMT5 & EGFR x cMet x cMet https://t.co/dZhGP99opA
-
RT @ApexOnco: Avenzo follows $BMY's lead as EGFR x HER3 becomes a hot target for bispecific ADCs https://t.co/ZoxEmAibo1 https://t.co/KfIle…